Tofactinib efficacy for treatment of ankylosing spondylitis comparable across different BMI's. Regardless of BMI, tofacitinib better than placebo. BMI <25: more AE and SAE Abs#0405 @RheumNow #ACR22 https://t.co/qs3U4mjUXD